A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations

被引：5
|
作者：
Hong, M. H. [1 ]
Spira, A. I. [2 ]
Lee, K. H. [3 ]
Cho, E. K. [4 ]
Han, J-Y. [5 ]
Shim, B. Y. [6 ]
Lee, J-S. [7 ]
Kao, S. C-H. [8 ]
Kim, S-W. [9 ]
Khattak, A. [10 ]
Patel, M. [11 ]
Xu, R. [11 ]
Wang, J. [11 ]
Ariazi, E. [12 ]
Daemen, A. [12 ]
Maneval, E. Chow [11 ]
Multani, P. S. [11 ]
Patel, R. [11 ]
Ahn, M-J. [13 ]
机构：
[1] Yonsei Univ, Severance Hosp, Dept Internal Med, Coll Med, Seoul, South Korea
[2] Virginia Canc Specialist & Next Oncol, Res Inst, Fairfax, VA USA
[3] Chungbuk Natl Univ Hosp, Dept Internal Med, Cheongju, South Korea
[4] Gachon Univ, Dept Internal Med, Gil Hosp, Incheon, South Korea
[5] Natl Canc Ctr, Ctr Lung Canc, Grad Sch Canc Sci & Policy, Goyang, South Korea
[6] Catholic Univ Korea, Dept Med Oncol, St Vincents Hosp, Suwon, South Korea
[7] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, Gyeonggi Do, South Korea
[8] Chris OBrien Lifehouse, Med Oncol Dept, Camperdown, NSW, Australia
[9] Univ Ulsan, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[10] Hollywood Med Ctr, One Clin Res, Med Oncol, Nedlands, WA, Australia
[11] ORIC Pharmaceut Inc, Clin Dev, San Diego, CA USA
[12] ORIC Pharmaceut Inc, Translat Med, San Diego, CA USA
[13] Sungkyunkwan Univ, Dept Hematol Oncol, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2366
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1333P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Anti-angiogenic Therapy or Immunotherapy? A Multicenter Study of Patients with Advanced NSCLC with EGFR / HER2 exon 20 Insertion Mutations
    Chu, T.
    Li, J.
    Xie, M.
    Zhao, R.
    Qiang, H.
    Chang, Q.
    Qian, J.
    Lu, H.
    Shen, Y.
    Han, Y.
    Su, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S628 - S628
  • [22] Phase 1 Dose-Escalation Study of the Investigational HER2/EGFR Inhibitor TAK-285 in Patients with Advanced Cancer
    LoRusso, P.
    Chiorean, E. G.
    Heath, E.
    Weise, A.
    Foley, M.
    Olivo, Y. S.
    Chi, X.
    Corvez, M.
    Venkatakrishnan, K.
    Sausville, E.
    CANCER RESEARCH, 2010, 70
  • [23] NVL-330 is a selective, brain-penetrant inhibitor of oncogenic HER2 exon 20 insertion mutations in preclinical models
    Andrews, K. L.
    Sun, Y.
    Gerard, B.
    Tangpeerachaikul, A.
    Mente, S.
    Kemper, R. A.
    Martin, C. M.
    Kohl, N. E.
    Horan, J. C.
    Pelish, H. E.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S76 - S77
  • [24] A phase 1b study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors
    Attard, G
    Kitzen, JJ
    de Bono, J
    Verweij, J
    Pronk, L
    Zhi, J
    Blagden, SP
    Reade, SE
    Zugmaier, G
    de Jonge, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 232S - 232S
  • [25] AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models
    Gonzalvez, Francois
    Zhu, Xiaotian
    Huang, Wei-Sheng
    Baker, Theresa E.
    Ning, Yaoyu
    Wardwell, Scott D.
    Nadworny, Sara
    Zhang, Sen
    Das, Biplab
    Gong, Yongjin
    Greenfield, Matthew T.
    Jang, Hyun G.
    Kohlmann, Anna
    Li, Feng
    Taslimi, Paul M.
    Tugnait, Meera
    Xu, Yongjin
    Ye, Emily Y.
    Youngsaye, Willmen W.
    Zech, Stephan G.
    Zhang, Yun
    Zhou, Tianjun
    Narasimhan, Narayana I.
    Dalgarno, David C.
    Shakespeare, William C.
    Rivera, Victor M.
    CANCER RESEARCH, 2016, 76
  • [26] Beamion Lung 1, a Phase Ia/Ib Trial of the HER2 TKI, BI 1810631 in Patients with Advanced Solid Tumors with HER2 Aberrations
    Yamamoto, N.
    Opdam, F.
    Barve, M.
    Tu, H. -Y.
    Wu, Y. -L.
    Schroeter, L.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S147 - S147
  • [27] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
    Sarina A. Piha-Paul
    Analía Azaro
    Hendrik Tobias Arkenau
    Do-Youn Oh
    Matthew D. Galsky
    Sumanta Kumar Pal
    Kensuke Hamada
    Yaohua He
    Ikuo Yamamiya
    Karim A Benhadji
    Antoine Hollebecque
    Investigational New Drugs, 2021, 39 : 1324 - 1334
  • [28] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
    Piha-Paul, Sarina A.
    Azaro, Analia
    Arkenau, Hendrik Tobias
    Oh, Do-Youn
    Galsky, Matthew D.
    Pal, Sumanta Kumar
    Hamada, Kensuke
    He, Yaohua
    Yamamiya, Ikuo
    Benhadji, Karim A.
    Hollebecque, Antoine
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1324 - 1334
  • [29] A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors.
    Plummer, R
    Vidal, L
    Perrett, R
    Shaw, H
    Pilkington, M
    Hanwell, J
    Temple, G
    Fong, P
    Amelsberg, A
    Calvert, H
    de Bono, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8990S - 8990S
  • [30] A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Wu, Y. L.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S1 - S1
12345